雙成藥業(002693.SZ):依替巴肽注射液獲得藥品註冊證書
格隆匯4月26日丨雙成藥業(002693.SZ)宣佈,公司於近日收到國家藥品監督管理局批准簽發的“依替巴肽注射液”《藥品註冊證書》,證書編號為2021S00382。
依替巴肽注射液用於急性冠狀動脈綜合徵(不穩定型心絞痛/非ST段抬高性心肌梗死)患者,包括接受藥物治療的患者和進行經皮冠狀動脈介入術(PCI)的患者,以降低死亡或新發生心肌梗死的聯合終點發生率;用於進行經皮冠狀動脈介入術(PCI)的患者,包括進行冠狀動脈內支架置入術的患者。以降低死亡、新發生心肌梗死或需要緊急介入治療的聯合終點發生率。
截至該公吿披露日,依替巴肽注射液(10ml:20mg)累計研發投入金額為人民幣1575.56萬元(未經審計)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.